Drugs / AHCC®
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06693323 | Dec 2024 → Dec 2027 expected | head and neck squamous cell carcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04633330 | Oct 2020 → Jun 2024 | human papilloma virus infection, squamous cell intraepithelial neoplasia | Shandong University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AHCC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06693323 ↗ |
| Known as | ECLM | “The proprietary, a standardized extract of cultured Lentinula edodes mycelia (ECLM), AHCC®” NCT04633330 ↗ |
| Route | Oral | “Given PO” NCT06693323 ↗ |